CORRECTION

Correction to: Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence

Joshua J. Gagne¹ · Jennifer M. Polinski¹ · Wenlei Jiang² · Sarah K. Dutcher² · Jing Xie¹ · Joyce Lii¹ · Lisa A. Fulchino¹ · Aaron S. Kesselheim¹

Published online: 8 March 2018
© Springer International Publishing AG, part of Springer Nature 2018

Correction to: Drugs 77(4): 427–433 (2017)
<https://doi.org/10.1007/s40265-017-0696-2>

Page 432, Fig. 2 Plots of model-based outcome incidence rates (per 100 person-years of exposure) before and after introduction of first generic versions of study and control drugs.

The original article can be found online at <https://doi.org/10.1007/s40265-017-0696-2>.

✉ Joshua J. Gagne
jgagne1@partners.org

¹ Program on Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St Suite 3030, Boston, MA 02120, USA

² Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

Previously presented as:

Should be presented as: